- Home
- NKSH vs ADAG Comparison
NKSH vs ADAG Comparison
Compare NKSH & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKSH | ADAG |
|---|---|---|
| Founded | 1891 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 260.3M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NKSH | ADAG |
|---|---|---|
| Price | $36.55 | $4.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 25.2K | ★ 270.7K |
| Earning Date | 04-23-2026 | 04-01-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ 100.81 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $8,176,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $46.86 | ★ N/A |
| Revenue Growth | ★ 9.39 | N/A |
| 52 Week Low | $27.00 | $1.44 |
| 52 Week High | $40.00 | $4.85 |
Technical Indicators
Market Signals| Indicator | NKSH | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 62.38 |
| Support Level | $35.02 | $3.21 |
| Resistance Level | $38.04 | $4.66 |
| Average True Range (ATR) | 1.21 | 0.45 |
| MACD | 0.11 | 0.09 |
| Stochastic Oscillator | 57.10 | 75.46 |
Price Performance
Historical ComparisonAbout NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.